Brief: Novocure To Present Data From Phase 3 Panova-3 Trial Of Tumor Treating Fields In Pancreatic Cancer At Esmo Gastrointestinal Cancers Congress 2025
01/07/2025 12:19
July 1 (Reuters) - Novocure Ltd NVCR.O: NOVOCURE TO PRESENT FINAL SECONDARY ENDPOINT DATA FROM THE PHASE 3 PANOVA-3 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) IN PANCREATIC CANCER AT THE ESMO GASTROINTESTINAL CANCERS CONGRESS 2025 Source text: ID:nBwcYLB6a Further company coverage: NVCR.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture